7/2/2009

The FDA is examining Sanofi-Aventis' insulin Lantus after reports released last week linked the drug to an increased risk of tumors. The move comes days after diabetes experts urged patients to continue using Lantus despite the possible risk.

Full Story:
Bloomberg

Related Summaries